The company’s three lead candidates target different cancer-associated proteins: HWK-007 targeting Protein Tyrosine Kinase 7 (PTK7), HWK-016 targeting Mucin 16 (MUC16), and HWK-206 targeting ...

AbbVie is nearing the completion of a phase 1 trial of another PTK7 ADC that began in 2020. SEZ6 is another target of interest for AbbVie, which is assessing ABBV-706 in a phase 1 trial.

IDEAYA Biosciences announced that Stu Dorman is joining the company as its chief commercial officer. 1 The precision medicine oncology company is preparing to shift to becoming a commercial launch ...

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen Monday, November 11, 2024 Drug News ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc.

IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) ...

Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) Option exercised for an exclusive worldwide ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential ...

BEIJING & SOUTH SAN FRANCISCO, Calif., November 11, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel ...